.jetcityimage/iStock Editorial through Getty Images Morgan Stanley has actually picked Eli Lilly (NYSE: LLY) as its own leading biopharma selection for 2025 and also ranked another 9 labels in the area as over weight. The assets banking company stated in a keep in mind that it continues to believe “diabesity is readied to come to be.